Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $1.00, $0.25 better than the analyst estimate of $0.75. Revenue for the quarter came in at $175.8 million versus the consensus estimate of $163.91 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.